Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy
暂无分享,去创建一个
J. Diallo | B. Dickinson | J. Bell | R. Marius | Julia Petryk | Ilson D. Sanders | N. Martin | J. Poutou | T. Azad | Bradley Austin | C. Ilkow | Zaid Taha | Sydney Vallati | Mathieu J. F. Crupi | Jack Whelan | Mason Boulanger | Tamara Burgess | Camille Victoor
[1] J. Diallo,et al. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer , 2022, Frontiers in Immunology.
[2] R. Vile,et al. Oncolytic virotherapy as immunotherapy , 2021, Science.
[3] yang-xin fu,et al. Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance , 2021, Nature Communications.
[4] J. Diallo,et al. Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection , 2021, Molecular Therapy.
[5] C. Verfaillie,et al. Doxycycline inducible overexpression systems: how to induce your gene of interest without inducing misinterpretations , 2021, Molecular biology of the cell.
[6] W. Bshara,et al. GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study , 2021, Clinical Cancer Research.
[7] A. Marchini,et al. Oncolytic Virus Immunotherapy , 2021, Cancers.
[8] Rosalie M Sterner,et al. CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.
[9] B. Becher,et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma , 2021, Nature Communications.
[10] Y. Pylayeva-Gupta,et al. IL-12 Family Cytokines in Cancer and Immunotherapy , 2021, Cancers.
[11] D. Zaharoff,et al. Localized Interleukin-12 for Cancer Immunotherapy , 2020, Frontiers in Immunology.
[12] C. Robert. A decade of immune-checkpoint inhibitors in cancer therapy , 2020, Nature Communications.
[13] Y. Fong,et al. Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges , 2020, Cancers.
[14] Stephen Boulton,et al. Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity , 2020, Expert opinion on biological therapy.
[15] Li Li,et al. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma , 2020, Science Translational Medicine.
[16] D. Altmann,et al. Antibiotic therapy and outcome from immune-checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.
[17] L. Zitvogel,et al. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Yuman Fong,et al. A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models , 2019, Cancer Gene Therapy.
[19] J. Bell,et al. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses , 2019, Stem cells.
[20] Jin Yu,et al. A Viral T7 RNA Polymerase Ratcheting Along DNA With Fidelity Control , 2019, Computational and structural biotechnology journal.
[21] B. Dickinson,et al. Evolution of C‐Terminal Modification Tolerance in Full‐Length and Split T7 RNA Polymerase Biosensors , 2019, Chembiochem : a European journal of chemical biology.
[22] N. Alharbi. Poxviral promoters for improving the immunogenicity of MVA delivered vaccines , 2018, Human vaccines & immunotherapeutics.
[23] S. Borkotoky,et al. The highly efficient T7 RNA polymerase: A wonder macromolecule in biological realm. , 2018, International journal of biological macromolecules.
[24] D. Bartlett,et al. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[25] J. Bell,et al. Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] Louai Labanieh,et al. Programming CAR-T cells to kill cancer , 2018, Nature Biomedical Engineering.
[27] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.
[28] R. Fouchier,et al. Armed oncolytic viruses: A kick-start for anti-tumor immunity , 2018, Cytokine & Growth Factor Reviews.
[29] Laurence Zitvogel,et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.
[30] M. Esteban,et al. Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Δ4 with a Set of Gene Deletions on Several Viral Pathways , 2017, Molecular therapy oncolytics.
[31] P. Pourquier,et al. Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer , 2015, BMC Cancer.
[32] G. Sutter,et al. Chapter Five Modified Vaccinia Virus Ankara History, Value in Basic Research, and Current Perspectives for Vaccine Development , 2017, Advances in Virus Research.
[33] M. Buñuales,et al. Adaptation of vectors and drug‐inducible systems for controlled expression of transgenes in the tumor microenvironment , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[34] L. Dyck,et al. Immune checkpoints and their inhibition in cancer and infectious diseases , 2017, European journal of immunology.
[35] Bryan C Dickinson,et al. Evolution of a split RNA polymerase as a versatile biosensor platform. , 2017, Nature chemical biology.
[36] F. Scialò,et al. Practical Recommendations for the Use of the GeneSwitch Gal4 System to Knock-Down Genes in Drosophila melanogaster , 2016, PloS one.
[37] X. Suo,et al. “Self-cleaving” 2A peptide from porcine teschovirus-1 mediates cleavage of dual fluorescent proteins in transgenic Eimeria tenella , 2016, Veterinary Research.
[38] A. Das,et al. Tet-On Systems For Doxycycline-inducible Gene Expression , 2016, Current gene therapy.
[39] F. Ginhoux,et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.
[40] Zhi-yong Ma,et al. Antiviral activity of doxycycline against vesicular stomatitis virus in vitro. , 2015, FEMS microbiology letters.
[41] K. McMasters,et al. Oncolytic Replication of E1b-Deleted Adenoviruses , 2015, Viruses.
[42] Troy Guthrie,et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] S. Cascinu,et al. Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data. , 2015, Clinical genitourinary cancer.
[44] J. Stritzker,et al. Inducible Gene Expression in Tumors Colonized by Modified Oncolytic Vaccinia Virus Strains , 2014, Journal of Virology.
[45] M. Lorenzo,et al. A Vaccinia Virus Recombinant Transcribing an Alphavirus Replicon and Expressing Alphavirus Structural Proteins Leads to Packaging of Alphavirus Infectious Single Cycle Particles , 2013, PloS one.
[46] P. Verardi,et al. Safety mechanism assisted by the repressor of tetracycline (SMART) vaccinia virus vectors for vaccines and therapeutics , 2013, Proceedings of the National Academy of Sciences.
[47] E. Raymond,et al. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? , 2008, British Journal of Cancer.
[48] F. Lang,et al. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[49] A. Mamelak,et al. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601) , 2007, Expert opinion on drug delivery.
[50] Jiwon Kim,et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[51] Harald Sontheimer,et al. Chlorotoxin Inhibits Glioma Cell Invasion via Matrix Metalloproteinase-2* , 2003, The Journal of Biological Chemistry.
[52] S. Yokoyama,et al. Structure of a T7 RNA polymerase elongation complex at 2.9 Å resolution , 2002, Nature.
[53] H. Sontheimer,et al. Chlorotoxin, a scorpion‐derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin , 2002, Glia.
[54] M. Gnant,et al. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. , 1999, Human gene therapy.
[55] L Adorini,et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. , 1998, Annual review of immunology.
[56] B. Moss,et al. Compact, synthetic, vaccinia virus early/late promoter for protein expression. , 1997, BioTechniques.
[57] B. Ryffel,et al. Effect of rapamycin on the expression of the IL‐2 receptor (CD25) , 1996, Clinical and experimental immunology.
[58] B. Moss,et al. Nonreplicating vaccinia vector efficiently expresses recombinant genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[59] M. Gossen,et al. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[60] P. Earl,et al. Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes , 1987, Molecular and cellular biology.
[61] P. Earl,et al. Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment , 1986, Journal of virology.
[62] B. Moss,et al. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.